March 27, 2023
Via: Medical Device NetworkBiotechnology firm Illumina and genomics company GenoScreen have introduced a new package that combines products from Illumina with the GenoScreen Deeplex Myc-TB assay, a next-generation sequencing (NGS)-based test for Tuberculosis (TB). As a targeted NGS-based test, the Deeplex Myc-TB assay […]
January 5, 2022
Via: HitConsultantBiomarker testing is used not only to select the most appropriate targeted oncology therapy available on the market for a particular patient but also to determine whether a patient’s best course of action is to receive an experimental therapy as […]
September 17, 2020
Via: medicaldevice-network.comUS-based biotechnology company Illumina is in talks to acquire cancer blood test developer Grail. Illumina is likely to pay more than $8bn for Grail, which is valued at approximately $6bn from its previous fundraisings, Bloomberg reported. According to the regulatory […]
January 12, 2017
Via: The Medical NewsIllumina, Inc. and Bio-Rad Laboratories, Inc. today announced the launch of the Illumina® Bio-Rad® Single-Cell Sequencing Solution at the J.P. Morgan Healthcare Conference. The comprehensive solution is the first next-generation sequencing (NGS) workflow for single-cell analysis, providing researchers the ability […]
January 6, 2017
Via: ForbesGrail, a San Francisco startup that aims to invent a blood test that can detect cancer early, announced this afternoon that it plans to raise $1 billion in venture capital in its second financing round, a sum that puts the biotech […]
July 19, 2024
Copyright © 2024. All rights reserved
